Loading

Avistone Biotechnology

June 03, 2024
Company Presentation
Oncology
Company Presentation Theater 1
Founded in 2010, Avistone Biotechnology is a private, global Oncology company, focused on targeted therapeutics. The company’s pipeline comprises of six assets, including: 1) Vebreltinib (PLB1001) (cMETi) which received conditional approval in China for MET Exon 14 Skipping NSCLC , 2) PLB1004 (EGFRi) for EGFR Exon 20 Insertion Mutations NSCLC, and 3) ANS014004 (ANS01), a next-generation Type II MET inhibitor, to be explored in NSCLC and other solid tumors. We are also exploring cMET/EGFR combinations with our clinical-stage Phase1b/2 development program investigating the combination of PLB1001 and PLB1004 in patients with metastatic NSCLC with MET amplification following EGFR-TKI failure in China. The company has over 200 employees globally with headquarters in Beijing, China. The company has raised $340 million in a Series A ($200M)and B ($140M) financing rounds. Investors include: Bain Capital, Vivo Capital, Primavera Capital, SDIC, IDG, Yanchaung Capital, and Cathay Capital.
Avistone Biotechnology
Company Website: http://en.avistonebio.com
Lead Product in Development: Vebreltinib (MET Exon 14 Skipping NSCLC)

Company HQ City

Chaoyang District

Company HQ State

Beijing

Company HQ Country

China

CEO/Top Company Official

Hepeng Shi, Ph.D. (CEO)

Development Phase of Primary Product

Other/Not Applicable
Speakers
David Chung
Chief Business Officer
Avistone Biotechnology
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS